Mongolia vs Montenegro: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Mongolia
- Montenegro
How they compare
Montenegro currently reports 18.1 deaths against 16.78 deaths in Mongolia, a difference of 1.32 deaths.
That makes Montenegro's figure about 1.1 times Mongolia's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Montenegro ahead.
Mongolia ranks 150th and Montenegro ranks 148th of 157 countries.
Across the 4 decades both report, Mongolia averaged higher in 2 and Montenegro in 2.
Head to head by decade
| Decade | Mongolia | Montenegro | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0.0409 deaths | 0.0409 deaths | Montenegro |
| 2000s | 0.4658 deaths | 2.41 deaths | 1.95 deaths | Montenegro |
| 2010s | 11.81 deaths | 8.06 deaths | 3.75 deaths | Mongolia |
| 2020s | 16.38 deaths | 14.86 deaths | 1.52 deaths | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Mongolia or Montenegro?
- Montenegro, at 18.1 deaths against 16.78 deaths in Mongolia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Mongolia and Montenegro?
- 1.32 deaths, with Montenegro ahead.
- How many years of comparable data are there for Mongolia and Montenegro?
- 35 years are reported by both, from 1990 to 2024.
- How do Mongolia and Montenegro rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Mongolia ranks 150th and Montenegro ranks 148th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.